With Gilead Sciences Inc. calling 2016 one of the company's strongest years for performance in the HIV space, promising Phase II data for its next-generation integrase inhibitor, bictegravir, could position the virology powerhouse to remain the HIV leader even after tenofovir alafenamide (TAF) loses patent protection in 2025.
The Foster City, CA-based biopharma presented data at the Conference on Retroviruses and Opportunistic Infections in Seattle Feb. 14 showing...






